SUMMARY OF PRODUCT CHARACTERISTICS. Excipients Butylhydroxyanisole E320 Butylhydroxytoluene E321
|
|
- Richard Allen
- 5 years ago
- Views:
Transcription
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pestigon 50 mg Spot-On Solution for Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One 0.5 ml pipette contains: Active Fipronil Excipients Butylhydroxyanisole E320 Butylhydroxytoluene E mg 0.1 mg 0.05 mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 Target Species Cats. 4.2 Indications for Use, Specifying the Target Species For the treatment of infestations by fleas (Ctenocephalides felis). The product shows immediate insecticidal effect and persistent insecticidal activity against new infestations by adult fleas for up to 5 weeks. The product shows acaricidal efficacy with killing effect against ticks (Ixodes ricinus) within 48 hours. The product has persistent acaricidal efficacy for up to 2 weeks against ticks (Dermacentor reticulatus). If ticks of this species are present when the product is applied, all ticks will not be killed within the first 48 hours but they may be killed within a week. The product can be used as part of a treatment programme for Flea Allergy Dermatitis where this has been previously diagnosed by a Veterinary Surgeon. Page 1 of 71
2 4.3 Contra-Indications In the absence of available data, the product should not be used on kittens less than 8 weeks old and/or weighing less than 1 kg. Do not use on sick (systemic diseases, fever ) or convalescent animals. Do not use in rabbits, as adverse drug reactions and even death could occur. Do not use in cases of known hypersensitivity to the active substance or to any of the excipients. 4.4 Special Warnings for Each Target Species The product does not prevent ticks from attaching to the animals. If the animal has been treated prior to exposure to the ticks, the ticks will start to be killed in the first hours after attachment. This will usually be prior to engorgement, minimising but not excluding the risk of transmission of diseases. Once dead ticks will often drop off the animal but any remaining ticks may be easily removed by a gentle pull. When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient and to other cats in the household are recommended. For optimum control of flea problems in a multi-pet household, all dogs and cats in the household should be treated with a suitable insecticide. Avoid frequent swimming or shampooing of the animal because the maintenance of effectiveness of the product in these cases has not been tested. Fleas from pets often infest the animal s basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. 4.5 Special Precautions for Use (i) Special precautions for use in animals Avoid contact with the animal s eyes. In the case of accidental eye contact immediately and thoroughly flush the eyes with water. It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment. Do not apply the product to wounds or damaged skin. Page 2 of 71
3 (ii) Special precautions to be taken by the person administering the veterinary medicinal product to the animals This product can cause mucous membrane and eye irritation. contact of the product with mouth and eyes should be avoided. Therefore, In case of accidental eye contact, immediately and thoroughly rinse eyes with plain water. If irritation to the eyes persists contact your doctor immediately and bring with you the package leaflet. Avoid contents coming into contact with the fingers. hands with soap and water. If this occurs, wash Wash hands after use. Do not smoke, drink or eat during application. People with a known hypersensitivity to fipronil or excipients (see section 6.1) should avoid contact with the veterinary medicinal product. Treated animals should not be handled until this application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children. Keep pipettes in original packaging and dispose of used pipettes immediately. (iii) Other precautions The alcohol carrier may have adverse effects on painted, varnished or other household surfaces or furnishings This product is flammable. Keep away from heat, sparks, open flame or other sources of ignition. 4.6 Adverse reactions (frequency and seriousness) If licking occurs, a brief period of hypersalivation may be observed due mainly to the nature of the carrier. Among the extremely rare suspected adverse reactions, transient cutaneous reactions at the application site (scaling, local alopecia, pruritus, erythema) and general pruritus or alopecia have been reported after use. Exceptionally, hypersalivation, reversible neurological signs (hyperaesthesia, depression, nervous signs) or vomiting have been observed after use. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) Page 3 of 71
4 - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use During Pregnancy, Lactation or Lay Laboratory studies using fipronil have not shown any evidence of teratogenic or embryotoxic effects. Studies have not been carried out with this product in pregnant and lactating animals. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment. 4.8 Interaction with Other Medicinal Products and Other Forms of Interaction None known. 4.9 Amounts to be Administered and Administration Route For external use only. Animals should be weighed accurately prior to treatment. Route of administration: By topical application to the skin. Dosage: 1 pipette of 0.5 ml per cat (approximately mg/kg). Method of Administration: Hold upright. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Break back the snap-off top from the spot-on pipette along the scored line. Part the coat between the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze gently to empty its contents onto the skin, preferably at two spots, one at the base of the skull and a second 2-3 cms further back. Page 4 of 71
5 It is important to ensure that the product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment. Care should be taken to avoid excessive wetting of the hair with the product since this will cause a sticky appearance of hairs at the treatment spot. However, should this occur, it will disappear within 24 hours post application. For optimal control of flea and/or tick infestation the treatment schedule can be based on the local epidemiological situation. In the absence of safety studies, the minimum treatment interval is 4 weeks Overdose (Symptoms, Emergency Procedures, Antidotes), if Necessary The toxicity of the product administered to the skin is very low. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal Periods Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Ectoparasiticides for topical use. ATCvet code: QP53AX Pharmacodynamic Properties Fipronil is an insecticide/acaricide in the phenylpyrazole family. It acts by inhibiting the GABA complex, binding to the chloride channel and thereby blocking pre- and post-synaptic transfer of chloride ions across the membrane. This results in uncontrolled activity of the central nervous system and death in insects and acarids. Fipronil exhibits insecticidal activity against fleas (Ctenocephalides felis), and acaricidal activity against ticks (Dermacentor reticulatus) in the cat. Newly arriving fleas are killed within 24 hours of landing on the animal. The product is effective against flea infestation for approximately 5 weeks and against tick (Dermacentor reticulatus) infestations for 2 weeks, depending on the level of challenge. 5.2 Pharmacokinetic Properties Fipronil is mainly metabolised to its sulfone derivative (RM1602), which also possesses insecticidal and acaricidal properties. Page 5 of 71
6 After a local application of fipronil to the cat, systemic absorption is negligible. The concentrations of fipronil on the hair decrease with time. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Povidone K12 Polysorbate 80 Butyl Alcohol Diethylene Glycol Monoethyl Ether 6.2 Incompatibilities None known. 6.3 Shelf-Life Shelf life of the veterinary medicinal product as packaged for sale: 3 years 6.4 Special Precautions for Storage This medicinal product does not require any special temperature storage conditions. Store in the original container in order to protect from light and moisture. 6.5 Nature and Composition of Immediate Packaging 0.5 ml pipette, moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4-ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes Not all pack sizes may be marketed. 6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from the Use of Such Products. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container. Page 6 of 71
7 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 03 July DATE OF REVISION OF THE TEXT May 2017 Approved: 08 May 2017 Page 7 of 71
8 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pestigon 67 mg Spot-On Solution for Small Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One 0.67 ml pipette contains: Active substance: Fipronil Excipients: Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) 67 mg mg mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 Target Species Dogs. 4.2 Indications for Use, Specifying the Target Species For the treatment of infestations by fleas (Ctenocephalides felis). The product shows immediate insecticidal effect and persistent insecticidal activity against new infestations by adult fleas for up to 8 weeks. The product has a persistent acaricidal efficacy against Ixodes ricinus for up to 2 weeks, Rhipicephalus sanguineus for up to 3 weeks and Dermacentor reticulatus for up to 4 weeks. If ticks of these species are present when the product is applied, all ticks will not be killed within the first 48 hours but they may be killed within a week. The product can be used as part of a treatment programme for Flea Allergy Dermatitis where this has been previously diagnosed by a Veterinary Surgeon. 4.3 Contra-Indications Do not use in dogs weighing less than 2 kg. Page 8 of 71
9 In the absence of available data, the product should not be used in puppies less than 8 weeks old. Do not use in sick (systemic diseases, fever ) or convalescent animals. Do not use in rabbits, as adverse reactions and even death could occur. This product is specifically developed for dogs. Do not use in cats, as this could lead to overdosing. Do not use in cases of known hypersensitivity to the active or to any of the excipients. 4.4 Special Warnings for Each Target Species The product does not prevent ticks from attaching to the animals, but ticks may be killed in the first hours after attachment prior to full engorgement and therefore minimising the risk of transmission of diseases. Once dead, ticks will often drop off the animal, but any remaining ticks may easily be removed by a gentle pull. When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient and to other dogs in the household are recommended. For optimal control of flea infestation in multi-pet household, all dogs and cats in the house should be treated with a suitable insecticide. Fleas from pets often infest the animal s basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. Avoid frequent swimming or shampooing of the animal because the maintenance of effectiveness of the product in these cases has not been tested. 4.5 Special Precautions for Use (i) Special precautions for use in animals Avoid contact with the animal s eyes. In the case of accidental eye contact immediately and thoroughly flush the eyes with water. It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment. Do not apply the product on wounds or damaged skin. Page 9 of 71
10 (ii) Special precautions to be taken by the person administering the veterinary medicinal product to the animals This product can cause mucous membrane and eye irritation. Therefore, contact of the product with the mouth and eyes should be avoided. In cases of accidental eye contact, immediately and thoroughly rinse the eye with plain water. If eye irritation persists seek medical advice and show the package leaflet or the label to a physician. People with a known hypersensitivity to fipronil or excipients (section 6.1) should avoid contact with the veterinary product. Avoid contents coming into contact with the fingers. hands with soap and water. If this occurs, wash Wash hands after use. Do not smoke, drink or eat during application. Treated animals should not be handled until this application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children. Keep pipettes in original packaging and dispose of used pipettes immediately. (iii) Other precautions Fipronil may adversely affect aquatic organisms. Dogs should not be allowed to swim in watercourses for 2 days after application. The alcohol carrier may have adverse effect on painted, varnished or other household surfaces or furnishings. This product is flammable. Keep away from heat, sparks, open flame or other sources of ignition. 4.6 Adverse reactions (frequency and seriousness) If licking occurs, a brief period of hypersalivation may be observed due mainly to the nature of the carrier. Among the extremely rare suspected adverse reactions, transient cutaneous reactions at the application site (skin discoloration, local alopecia, pruritus, erythema) and general pruritus or alopecia have been reported after use. Exceptionally, hypersalivation, reversible neurological signs (hyperaesthesia, depression, nervous signs), vomiting or respiratory signs have been observed after use. The frequency of adverse reactions is defined using the following convention: Page 10 of 71
11 - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use During Pregnancy, Lactation or Lay Laboratory studies using fipronil have not shown any evidence of teratogenic or embryotoxic effects. Studies have not been carried out with this product in pregnant and lactating animals. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment. 4.8 Interaction with Other Medicinal Products and Other Forms of Interaction None known. 4.9 Amounts to be Administered and Administration Route Route of administration: By topical application to the skin. For external use only. Apply the product directly to the skin based on weight of the animal. Animals should be weighed accurately prior to treatment. Dosage 1 pipette of 0.67 ml per dog weighing over 2 kg and up to 10 kg bodyweight. Method of Administration: Hold upright. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Break back the snap-off top from the spot-on pipette along the scored line. Part the coat between the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze gently at one or two spots to empty its contents onto the skin. Page 11 of 71
12 It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that the animals do not lick each other following treatment. Care should be taken to avoid excessive wetting of the hair with the product since this will cause a sticky appearance of hairs at the treatment spot. However, should this occur, it will disappear within 48 hours post application. For the optimal control of infestation by flea and or/tick the treatment schedule can be based on local epidemiological situation. In the absence of safety studies, the minimum treatment interval is 4 weeks Overdose (Symptoms, Emergency Procedures, Antidotes), if Necessary No adverse effects were observed in target animal safety studies in 8 week old puppies, growing dogs and dogs weighing circa 2kg treated on 3 occasions at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal Periods Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Ectoparasiticides for topical use. ATC Vet Code: QP53AX Pharmacodynamic Properties Fipronil is an insecticide/acaricide in the phenylpyrazole family. It acts by inhibiting the GABA complex, binding to the chloride channel and thereby blocking pre- and post-synaptic transfer of chloride ions across the cell membrane. This results in uncontrolled activity of the central nervous system and death in insects and acarids. Fipronil exhibits insecticidal activity against fleas (Ctenocephalides felis), and acaricidal activity against ticks (Rhipicephalus sanguineus, Dermacentor reticulatus, Ixodes ricinus) in the dog. Newly arriving fleas are killed within 24 hours of landing on the animal. Ticks if already present at the time of application of the product, may not always be killed in the first 48 hours, however will be killed within 9 days post treatment. The product is effective against flea infestation (Ctenocephalides felis) for approximately 8 weeks and against tick infestations for up to 4 weeks (see indications for use), depending on the tick species and the level of challenge. Page 12 of 71
13 5.2 Pharmacokinetic Particulars After a local application of fipronil to the dog, it is slightly absorbed through the skin. Low levels of fipronil may be detected in the plasma, with a very high variability between dogs. After application, there is a good distribution of the chemical on the hair, presenting a good gradient of concentration between the application zone and the peripheral area. Fipronil is mainly metabolised to its sulfone derivative (RM1602), which also possesses insecticidal and acaricidal properties. The concentrations of fipronil on the hair decrease with time. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Povidone K12 Polysorbate 80 Butyl Alcohol Diethylene Glycol Monoethyl Ether 6.2 Incompatibilities None known. 6.3 Shelf-Life Shelf life of the veterinary medicinal product as packaged for sale: 3 years 6.4 Special Precautions for Storage This medicinal product does not require any special temperature storage conditions. Store in the original container in order to protect from light and moisture. 6.5 Nature and Composition of Immediate Packaging 0.67 ml pipette, moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4-ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes Not all pack sizes may be marketed. Page 13 of 71
14 6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from the Use of Such Products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Newry Co. Down BT35 6JP United Kingdom 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 04 July DATE OF REVISION OF THE TEXT June 2017 Approved: 14 June 2017 Page 14 of 71
15 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pestigon 134 mg Spot-On Solution for Medium Dogs 3. QUALITATIVE AND QUANTITATIVE COMPOSITION One 1.34 ml pipette contains: Active substance: Fipronil Excipients: Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) 134 mg mg mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 Target Species Dogs. 4.2 Indications for Use, Specifying the Target Species For the treatment of infestations by fleas (Ctenocephalides felis). The product shows immediate insecticidal effect and persistent insecticidal activity against new infestations by adult fleas for up to 8 weeks. The product has a persistent acaricidal efficacy against Ixodes ricinus for up to 2 weeks, Rhipicephalus sanguineus for up to 3 weeks and Dermacentor reticulatus for up to 4 weeks. If ticks of these species are present when the product is applied, all ticks will not be killed within the first 48 hours but they may be killed within a week. The product can be used as part of a treatment programme for Flea Allergy Dermatitis where this has been previously diagnosed by a Veterinary Surgeon. 4.3 Contra-Indications Page 15 of 71
16 Do not use in dogs weighing less than 10 kg. In the absence of available data, the product should not be used in puppies less than 8 weeks old. Do not use in sick (systemic diseases, fever ) or convalescent animals. Do not use in rabbits, as adverse reactions and even death could occur. This product is specifically developed for dogs. Do not use in cats, as this could lead to overdosing. Do not use in cases of known hypersensitivity to the active or to any of the excipients. 4.4 Special Warnings for Each Target Species The product does not prevent ticks from attaching to the animals, but ticks may be killed in the first hours after attachment prior to full engorgement and therefore minimising the risk of transmission of diseases. Once dead, ticks will often drop off the animal, but any remaining ticks may easily be removed by a gentle pull. When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient and to other dogs in the household are recommended. For optimal control of flea infestation in multi-pet household, all dogs and cats in the house should be treated with a suitable insecticide. Fleas from pets often infest the animal s basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. Avoid frequent swimming or shampooing of the animal because the maintenance of effectiveness of the product in these cases has not been tested. 4.5 Special Precautions for Use (i) Special precautions for use in animals Avoid contact with the animal s eyes.in the case of accidental eye contact immediately and thoroughly flush the eyes with water. It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment. Page 16 of 71
17 Do not apply the product on wounds or damaged skin. (ii) Special precautions to be taken by the person administering the veterinary medicinal product to the animals This product can cause mucous membrane and eye irritation. Therefore, contact of the product with the mouth and eyes should be avoided. In cases of accidental eye contact, immediately and thoroughly rinse the eye with plain water. If eye irritation persists seek medical advice and show the package leaflet or the label to a physician. People with a known hypersensitivity to fipronil or excipients (section 6.1) should avoid contact with the veterinary product. Avoid contents coming into contact with the fingers. hands with soap and water. If this occurs, wash Wash hands after use. Do not smoke, drink or eat during application. Treated animals should not be handled until this application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children. Keep pipettes in original packaging and dispose of used pipettes immediately. (iii) Other precautions Fipronil may adversely affect aquatic organisms. Dogs should not be allowed to swim in watercourses for 2 days after application. The alcohol carrier may have adverse effect on painted, varnished or other household surfaces or furnishings. This product is flammable. Keep away from heat, sparks, open flame or other sources of ignition. 4.6 Adverse reactions (frequency and seriousness) If licking occurs, a brief period of hypersalivation may be observed due mainly to the nature of the carrier. Among the extremely rare suspected adverse reactions, transient cutaneous reactions at the application site (skin discoloration, local alopecia, pruritus, erythema) and general pruritus or alopecia have been reported after use. Exceptionally, hypersalivation, reversible neurological signs (hyperaesthesia, depression, nervous signs), vomiting or respiratory signs have been observed after use. Page 17 of 71
18 The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use During Pregnancy, Lactation or Lay Laboratory studies using fipronil have not shown any evidence of teratogenic or embryotoxic effects. Studies have not been carried out with this product in pregnant and lactating animals. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment. 4.8 Interaction with Other Medicinal Products and Other Forms of Interaction None known. 4.9 Amounts to be Administered and Administration Route Route of administration: By topical application to the skin. For external use only. Apply the product directly to the skin based on weight of the animal. Animals should be weighed accurately prior to treatment. Dosage 1 pipette of 1.34 ml per dog weighing over 10 kg and up to 20 kg bodyweight. Method of Administration: Hold upright. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Break back the snap-off top from the spot-on pipette along the scored line. Part the coat between the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze gently at one or two spots to empty its contents onto the skin. Page 18 of 71
19 It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that the animals do not lick each other following treatment. Care should be taken to avoid excessive wetting of the hair with the product since this will cause a sticky appearance of hairs at the treatment spot. However, should this occur, it will disappear within 48 hours post application. For the optimal control of infestation by flea and or/tick the treatment schedule can be based on local epidemiological situation. In the absence of safety studies, the minimum treatment interval is 4 weeks Overdose (Symptoms, Emergency Procedures, Antidotes), if Necessary No adverse effects were observed in target animal safety studies in 8 week old puppies, growing dogs and dogs weighing circa 2kg treated on 3 occasions at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal Periods Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Ectoparasiticides for topical use. ATC Vet Code: QP53AX Pharmacodynamic Properties Fipronil is an insecticide/acaricide in the phenylpyrazole family. It acts by inhibiting the GABA complex, binding to the chloride channel and thereby blocking pre- and post-synaptic transfer of chloride ions across the cell membrane. This results in uncontrolled activity of the central nervous system and death in insects and acarids. Fipronil exhibits insecticidal activity against fleas (Ctenocephalides felis), and acaricidal activity against ticks (Rhipicephalus sanguineus,dermacentor reticulatus, Ixodes ricinus) in the dog. Newly arriving fleas are killed within 24 hours of landing on the animal. Ticks if already present at the time of application of the product, may not always be killed in the first 48 hours, however will be killed within 9 days post treatment. Page 19 of 71
20 The product is effective against flea infestation (Ctenocephalides felis) for approximately 8 weeks and against tick infestations for up to 4 weeks (see indications for use), depending on the tick species and the level of challenge. 5.2 Pharmacokinetic Particulars After a local application of fipronil to the dog, it is slightly absorbed through the skin. Low levels of fipronil may be detected in the plasma, with a very high variability between dogs. After application, there is a good distribution of the chemical on the hair, presenting a good gradient of concentration between the application zone and the peripheral area. Fipronil is mainly metabolised to its sulfone derivative (RM1602), which also possesses insecticidal and acaricidal properties. The concentrations of fipronil on the hair decrease with time. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Povidone K12 Polysorbate 80 Butyl Alcohol Diethylene Glycol Monoethyl Ether 6.2 Incompatibilities None known. 6.3 Shelf-Life Shelf life of the veterinary medicinal product as packaged for sale: 3 years 6.4 Special Precautions for Storage This medicinal product does not require any special temperature storage conditions. Store in the original container in order to protect from light and moisture. 6.5 Nature and Composition of Immediate Packaging 1.34 ml, pipette moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within Page 20 of 71
21 a child resistant 4-ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes Not all pack sizes may be marketed. 6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from the Use of Such Products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 06 July DATE OF REVISION OF THE TEXT June 2017 Approved 13 July 2017 Page 21 of 71
22 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pestigon 268 mg Spot-On Solution for Large Dogs 4. QUALITATIVE AND QUANTITATIVE COMPOSITION One 2.68 ml pipette contains: Active substance: Fipronil Excipients: Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) 268 mg mg mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 Target Species Dogs. 4.2 Indications for Use, Specifying the Target Species For the treatment of infestations by fleas (Ctenocephalides felis). The product shows immediate insecticidal effect and persistent insecticidal activity against new infestations by adult fleas for up to 8 weeks. The product has a persistent acaricidal efficacy against Ixodes ricinus for up to 2 weeks, Rhipicephalus sanguineus for up to 3 weeks and Dermacentor reticulatus for up to 4 weeks. If ticks of these species are present when the product is applied, all ticks will not be killed within the first 48 hours but they may be killed within a week. The product can be used as part of a treatment programme for Flea Allergy Dermatitis where this has been previously diagnosed by a Veterinary Surgeon. Page 22 of 71
23 4.3 Contra-Indications Do not use in dogs weighing less than 20 kg. In the absence of available data, the product should not be used in puppies less than 8 weeks old. Do not use in sick (systemic diseases, fever ) or convalescent animals. Do not use in rabbits, as adverse reactions and even death could occur. This product is specifically developed for dogs. Do not use in cats, as this could lead to overdosing. Do not use in cases of known hypersensitivity to the active or to any of the excipients. 4.4 Special Warnings for Each Target Species The product does not prevent ticks from attaching to the animals, but ticks may be killed in the first hours after attachment prior to full engorgement and therefore minimising the risk of transmission of diseases. Once dead, ticks will often drop off the animal, but any remaining ticks may easily be removed by a gentle pull. When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient and to other dogs in the household are recommended. For optimal control of flea infestation in multi-pet household, all dogs and cats in the house should be treated with a suitable insecticide. Fleas from pets often infest the animal s basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. Avoid frequent swimming or shampooing of the animal because the maintenance of effectiveness of the product in these cases has not been tested. 4.5 Special Precautions for Use (i) Special precautions for use in animals Avoid contact with the animal s eyes. In the case of accidental eye contact immediately and thoroughly flush the eyes with water. It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment. Page 23 of 71
24 Do not apply the product on wounds or damaged skin. (ii) Special precautions to be taken by the person administering the veterinary medicinal product to the animals This product can cause mucous membrane and eye irritation. Therefore, contact of the product with the mouth and eyes should be avoided. In cases of accidental eye contact, immediately and thoroughly rinse the eye with plain water. If eye irritation persists seek medical advice and show the package leaflet or the label to a physician. People with a known hypersensitivity to fipronil or excipients (section 6.1) should avoid contact with the veterinary product. Avoid contents coming into contact with the fingers. hands with soap and water. If this occurs, wash Wash hands after use. Do not smoke, drink or eat during application. Treated animals should not be handled until this application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children. Keep pipettes in original packaging and dispose of used pipettes immediately. (iii) Other precautions Fipronil may adversely affect aquatic organisms. Dogs should not be allowed to swim in watercourses for 2 days after application. The alcohol carrier may have adverse effect on painted, varnished or other household surfaces or furnishings. This product is flammable. Keep away from heat, sparks, open flame or other sources of ignition. 4.6 Adverse reactions (frequency and seriousness) If licking occurs, a brief period of hypersalivation may be observed due mainly to the nature of the carrier. Among the extremely rare suspected adverse reactions, transient cutaneous reactions at the application site (skin discoloration, local alopecia, pruritus, erythema) and general pruritus or alopecia have been reported after use. Exceptionally, hypersalivation, reversible neurological signs (hyperaesthesia, depression, nervous signs), vomiting or respiratory signs have been observed after use. Page 24 of 71
25 The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use During Pregnancy, Lactation or Lay Laboratory studies using fipronil have not shown any evidence of teratogenic or embryotoxic effects. Studies have not been carried out with this product in pregnant and lactating animals. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment. 4.8 Interaction with Other Medicinal Products and Other Forms of Interaction None known. 4.9 Amounts to be Administered and Administration Route Route of administration: By topical application to the skin. For external use only. Apply the product directly to the skin based on weight of the animal. Animals should be weighed accurately prior to treatment. Dosage 1 pipette of 2.68 ml per dog weighing over 20 kg and up to 40 kg bodyweight. For dogs over 60 kg use two pipettes of 2.68 ml. Method of Administration: Hold upright. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Break back the snap-off top from the spot-on pipette along the scored line. Part the coat between the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze gently at one or two spots to empty its contents onto the skin. Page 25 of 71
26 It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that the animals do not lick each other following treatment. Care should be taken to avoid excessive wetting of the hair with the product since this will cause a sticky appearance of hairs at the treatment spot. However, should this occur, it will disappear within 48 hours post application. For the optimal control of infestation by flea and or/tick the treatment schedule can be based on local epidemiological situation. In the absence of safety studies, the minimum treatment interval is 4 weeks Overdose (Symptoms, Emergency Procedures, Antidotes), if Necessary No adverse effects were observed in target animal safety studies in 8 week old puppies, growing dogs and dogs weighing circa 2kg treated on 3 occasions at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal Periods Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Ectoparasiticides for topical use. ATC Vet Code: QP53AX Pharmacodynamic Properties Fipronil is an insecticide/acaricide in the phenylpyrazole family. It acts by inhibiting the GABA complex, binding to the chloride channel and thereby blocking pre- and post-synaptic transfer of chloride ions across the cell membrane. This results in uncontrolled activity of the central nervous system and death in insects and acarids. Fipronil exhibits insecticidal activity against fleas (Ctenocephalides felis), and acaricidal activity against ticks (Rhipicephalus sanguineus, Dermacentor reticulatus, Ixodes ricinus) in the dog. Newly arriving fleas are killed within 24 hours of landing on the animal. Ticks if already present at the time of application of the product, may not always be killed in the first 48 hours, however will be killed within 9 days post treatment. The product is effective against flea infestation (Ctenocephalides felis) for approximately 8 weeks and against tick infestations for up to 4 weeks (see indications for use), depending on the tick species and the level of challenge. Page 26 of 71
27 5.2 Pharmacokinetic Particulars After a local application of fipronil to the dog, it is slightly absorbed through the skin. Low levels of fipronil may be detected in the plasma, with a very high variability between dogs. After application, there is a good distribution of the chemical on the hair, presenting a good gradient of concentration between the application zone and the peripheral area. Fipronil is mainly metabolised to its sulfone derivative (RM1602), which also possesses insecticidal and acaricidal properties. The concentrations of fipronil on the hair decrease with time. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Povidone K12 Polysorbate 80 Butyl Alcohol Diethylene Glycol Monoethyl Ether 6.2 Incompatibilities None known. 6.3 Shelf-Life Shelf life of the veterinary medicinal product as packaged for sale: 3 years 6.4 Special Precautions for Storage This medicinal product does not require any special temperature storage conditions. Store in the original container in order to protect from light and moisture. 6.5 Nature and Composition of Immediate Packaging 2.68 ml, pipette moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4-ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes Not all pack sizes may be marketed. Page 27 of 71
28 6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from the Use of Such Products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 06 July DATE OF REVISION OF THE TEXT June 2017 Approved 13 June 2017 Page 28 of 71
29 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pestigon 402 mg Spot-On Solution for Very Large Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One 4.02 ml pipette contains Active substance: Fipronil Excipients: Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) 402 mg mg mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 Target Species Dogs. 4.2 Indications for Use, Specifying the Target Species For the treatment of infestations by fleas (Ctenocephalides felis). The product shows immediate insecticidal effect and persistent insecticidal activity against new infestations by adult fleas for up to 8 weeks. The product has a persistent acaricidal efficacy against Ixodes ricinus for up to 2 weeks, Rhipicephalus sanguineus for up to 3 weeks and Dermacentor reticulatus for up to 4 weeks. If ticks of these species are present when the product is applied, all ticks will not be killed within the first 48 hours but they may be killed within a week. The product can be used as part of a treatment programme for Flea Allergy Dermatitis where this has been previously diagnosed by a Veterinary Surgeon. 4.3 Contra-Indications Do not use in dogs weighing less than 40 kg. In the absence of available data, the product should not be used in puppies less than 8 weeks old. Page 29 of 71
30 Do not use in sick (systemic diseases, fever ) or convalescent animals. Do not use in rabbits, as adverse reactions and even death could occur. This product is specifically developed for dogs. Do not use in cats, as this could lead to overdosing. Do not use in cases of known hypersensitivity to the active or to any of the excipients. 4.4 Special Warnings for Each Target Species The product does not prevent ticks from attaching to the animals, but ticks may be killed in the first hours after attachment prior to full engorgement and therefore minimising the risk of transmission of diseases. Once dead, ticks will often drop off the animal, but any remaining ticks may easily be removed by a gentle pull. When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient and to other dogs in the household are recommended. For optimal control of flea infestation in multi-pet household, all dogs and cats in the house should be treated with a suitable insecticide. Fleas from pets often infest the animal s basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. Avoid frequent swimming or shampooing of the animal because the maintenance of effectiveness of the product in these cases has not been tested. 4.5 Special Precautions for Use (i) Special precautions for use in animals Avoid contact with the animal s eyes.in the case of accidental eye contact immediately and thoroughly flush the eyes with water. It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment. Do not apply the product on wounds or damaged skin. Page 30 of 71
31 (ii) Special precautions to be taken by the person administering the veterinary medicinal product to the animals This product can cause mucous membrane and eye irritation. Therefore, contact of the product with the mouth and eyes should be avoided. In cases of accidental eye contact, immediately and thoroughly rinse the eye with plain water. If eye irritation persists seek medical advice and show the package leaflet or the label to a physician. People with a known hypersensitivity to fipronil or excipients (section 6.1) should avoid contact with the veterinary product. Avoid contents coming into contact with the fingers. hands with soap and water. If this occurs, wash Wash hands after use. Do not smoke, drink or eat during application. Treated animals should not be handled until this application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children. Keep pipettes in original packaging and dispose of used pipettes immediately. (iii) Other precautions Fipronil may adversely affect aquatic organisms. Dogs should not be allowed to swim in watercourses for 2 days after application. The alcohol carrier may have adverse effect on painted, varnished or other household surfaces or furnishings. This product is flammable. Keep away from heat, sparks, open flame or other sources of ignition. 4.6 Adverse reactions (frequency and seriousness) If licking occurs, a brief period of hypersalivation may be observed due mainly to the nature of the carrier. Among the extremely rare suspected adverse reactions, transient cutaneous reactions at the application site (skin discoloration, local alopecia, pruritus, erythema) and general pruritus or alopecia have been reported after use. Exceptionally, hypersalivation, reversible neurological signs (hyperaesthesia, depression, nervous signs), vomiting or respiratory signs have been observed after use. Page 31 of 71
32 The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use During Pregnancy, Lactation or Lay Laboratory studies using fipronil have not shown any evidence of teratogenic or embryotoxic effects. Studies have not been carried out with this product in pregnant and lactating animals. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment. 4.8 Interaction with Other Medicinal Products and Other Forms of Interaction None known. 4.9 Amounts to be Administered and Administration Route Route of administration: By topical application to the skin. For external use only. Apply the product directly to the skin based on weight of the animal. Animals should be weighed accurately prior to treatment. Dosage 1 pipette of 4.02 ml per dog weighing over 40 kg and up to 60 kg bodyweight. For dogs over 60 kg use two pipettes of 2.68 ml. Method of Administration: Hold upright. Tap the narrow part of the pipette to ensure the contents are within the main body of the pipette. Break back the snap-off top from the spot-on pipette along the scored line. Part the coat between the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze gently at one or two spots to empty its contents onto the skin. Page 32 of 71
33 It is important to make sure that the product is applied to an area where the animal cannot lick it off, and to make sure that the animals do not lick each other following treatment. Care should be taken to avoid excessive wetting of the hair with the product since this will cause a sticky appearance of hairs at the treatment spot. However, should this occur, it will disappear within 48 hours post application. For the optimal control of infestation by flea and or/tick the treatment schedule can be based on local epidemiological situation. In the absence of safety studies, the minimum treatment interval is 4 weeks Overdose (Symptoms, Emergency Procedures, Antidotes), if Necessary No adverse effects were observed in target animal safety studies in 8 week old puppies, growing dogs and dogs weighing circa 2kg treated on 3 occasions at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal Periods Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic Group: Ectoparasiticides for topical use. ATC Vet Code: QP53AX Pharmacodynamic Properties Fipronil is an insecticide/acaricide in the phenylpyrazole family. It acts by inhibiting the GABA complex, binding to the chloride channel and thereby blocking pre- and post-synaptic transfer of chloride ions across the cell Page 33 of 71
34 Page 34 of 71 membrane. This results in uncontrolled activity of the central nervous system and death in insects and acarids. Fipronil exhibits insecticidal activity against fleas (Ctenocephalides felis), and acaricidal activity against ticks (Rhipicephalus sanguineus, Dermacentor reticulatus, Ixodes ricinus) in the dog. Newly arriving fleas are killed within 24 hours of landing on the animal. Ticks if already present at the time of application of the product, may not always be killed in the first 48 hours, however will be killed within 9 days post treatment. The product is effective against flea infestation (Ctenocephalides felis) for approximately 8 weeks and against tick infestations for up to 4 weeks (see indications for use), depending on the tick species and the level of challenge. 5.2 Pharmacokinetic Particulars After a local application of fipronil to the dog, it is slightly absorbed through the skin. Low levels of fipronil may be detected in the plasma, with a very high variability between dogs. After application, there is a good distribution of the chemical on the hair, presenting a good gradient of concentration between the application zone and the peripheral area. Fipronil is mainly metabolised to its sulfone derivative (RM1602), which also possesses insecticidal and acaricidal properties. The concentrations of fipronil on the hair decrease with time. 6. PHARMACEUTICAL PARTICULARS 6.1 List of Excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Povidone K12 Polysorbate 80 Butyl Alcohol Diethylene Glycol Monoethyl Ether 6.2 Incompatibilities None known. 6.3 Shelf-Life Shelf life of the veterinary medicinal product as packaged for sale: 3 years 6.4 Special Precautions for Storage This medicinal product does not require any special temperature storage conditions.
35 Store in the original container in order to protect from light and moisture. 6.5 Nature and Composition of Immediate Packaging 4.02 ml, pipette moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4-ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes Not all pack sizes may be marketed. 6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from the Use of Such Products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Fipronil may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited, Station Works, Newry, Co. Down, BT35 6JP, United Kingdom 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 06 July DATE OF REVISION OF THE TEXT June 2017 Approved: 14 June 2017 Page 35 of 71
36 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PestiGon Combo 50 mg / 60 mg spot-on solution for cats and ferrets (IE, BG, FR, HR, CY, CZ, EE, EL, HU, IT, LV, LT, MT, PT, RO, SK, ES, UK) Bolfo Combo 50 mg / 60 mg spot-on solution for cats and ferrets (DE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pipette of 0.5 ml contains: Active substances: Fipronil mg (S)-methoprene mg Excipients: Butylhydroxyanisole (E320) mg Butylhydroxytoluene (E321) mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, yellow solution. 4. CLINICAL PARTICULARS 4.1 Target species Cats and ferrets. 4.2 Indications for use, specifying the target species In cats: To be used against infestations with fleas, alone or in association with ticks and/or biting lice. Elimination of fleas (Ctenocephalides spp.). Insecticidal efficacy against new infestations with adult fleas persists for 4 weeks. Prevention of the multiplication of fleas by inhibiting the development of eggs (ovicidal activity), larvae and pupae (larvicidal activity) originating from eggs laid by adult fleas for six weeks after application. Elimination of ticks (Ixodes ricinus, Dermacentor variabilis, Rhipicephalus sanguineus). The product has a persistent acaricidal efficacy for up to 2 weeks against ticks (based on experimental data). Elimination of biting lice (Felicola subrostratus). The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). Page 36 of 71
37 In ferrets: To be used against infestations with fleas, alone or in association with ticks. Elimination of fleas (Ctenocephalides spp.). Insecticidal efficacy against new infestations with adult fleas persists for 4 weeks. Prevention of the multiplication of fleas by inhibiting the development of eggs (ovicidal activity), larvae and pupae (larvicidal activity) originating from eggs laid by adult fleas. Elimination of ticks (Ixodes ricinus). The product has a persistent acaricidal efficacy for 4 weeks against ticks (based on experimental data). 4.3 Contraindications In the absence of available data, the product should not be used on kittens less than 8 weeks old and/or weighing less than 1 kg. The product should not be used on ferrets less than 6 months old. Do not use on sick (e.g. systemic diseases, fever) or convalescent animals. Do not use in rabbits, as adverse drug reactions with even mortality could occur. In absence of studies, the use of the product is not recommended in non-target species. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 4.4 Special warnings for each target species Avoid contact with the animal s eyes. 4.5 Special precautions for use Special precautions for use in animals It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment. No data on the effect of bathing/shampooing on the efficacy of the product in cats and ferrets are available. However, based on information available for dogs shampooed as from 2 days after application of the product, it is not recommended to bath animals within 2 days after application of the product. There may be an attachment of single ticks. For this reason a transmission of infectious diseases cannot be completely excluded if conditions are unfavourable. Fleas from pets often infest the animal s basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. The potential toxicity of the product for kittens of less than 8 weeks of age in contact with a treated queen is not documented. Special care should be taken in this case. Page 37 of 71
38 Special precautions to be taken by the person administering the veterinary medicinal product to animals This product can cause mucous membrane, skin and eye irritation. Therefore, contact of the product with mouth, skin and eyes should be avoided. In case of accidental eye contact, immediately and thoroughly rinse the eyes with clean water. If eye irritation persists seek medical advice and show the package leaflet or the label to the physician. If contact with the skin occurs, wash hands with soap and water. People with a known hypersensitivity to insecticides or alcohol should avoid contact with the veterinary medicinal product. Wash hands after use. Ingestion of the product is harmful. Prevent children getting access to the pipettes and discard the used pipettes immediately after applying the product. In case of accidental ingestion of product, seek medical advice immediately. Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children. 4.6 Adverse reactions (frequency and seriousness) Do not overdose. Cats: Among the very rare suspected adverse reactions, transient skin reactions on the application site (scaling, local hair loss, itching, redness) and general itching or hair loss have been reported after use. Excessive salivation, reversible nervous signs (increased sensitivity to stimulation, depression, other nervous signs) or vomiting have also been observed after use. The frequency of adverse reactions is defined using the following convention: - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). If licking occurs, a brief period of excessive salivation may be observed due mainly to the nature of the carrier. 4.7 Use during pregnancy, lactation or lay Cats: The product can be used during pregnancy. For treatment during the lactating period, see section 4.5 i). Ferrets: Page 38 of 71
39 Laboratory studies in cats have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. The safety of the veterinary medicinal product has not been established in ferrets during pregnancy and lactation. Use only according to the risk-benefit assessment by the responsible veterinarian. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route Dosage: One pipette of 0.5 ml per cat, corresponding to a minimum recommended dose of 5 mg/kg for fipronil and 6 mg/kg for (S)-methoprene. In the absence of safety studies, the minimum treatment interval is 4 weeks. One pipette of 0.5 ml per ferret corresponding to a dose of 50 mg for fipronil and 60 mg for (S)-methoprene per ferret. The minimum treatment interval is 4 weeks. Route of administration: External use only, spot-on use.. Only remove pipette from sachet immediately prior to use. Method of Administration: Remove the pipette from the outer sachet using scissors or fold along diagonal line to expose nick; tear back at nick. Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Twist or snap back the tip. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze the Page 39 of 71
40 pipette several times to empty its contents completely and directly onto the skin in one spot. Temporary changes to the coat (clumped/greasy hair) may be noted at the application site Overdose (symptoms, emergency procedures, antidotes), if necessary The risk of experiencing adverse effects may increase with overdosing (see section 4.6). In cats: No undesirable effects were observed in target animal safety studies in cats and kittens aged 8 weeks and older and weighing about 1 kg treated once a month at five times the recommended dose for six consecutive months. Itching may occur following treatment. Overdose application of the product will cause a sticky appearance of hairs at the treatment spot. However, should this occur, it will disappear within 24 hours post application. In ferrets: In ferrets aged 6 months and older and treated once every 2 weeks for four treatments, at five times the recommended dose, body weight loss was observed in some animals Withdrawal period(s) Not applicable. 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Ectoparasiticides for topical use, fipronil combinations. ATCvet code: QP53AX Pharmacodynamic properties Fipronil is an insecticide and acaricide belonging to the phenylpyrazole family. It acts by interacting with ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarines. Fipronil kills fleas within 24 hours, ticks (Dermacentor variabilis, Rhipicephalus sanguineus, Ixodes scapularis, Ixodes ricinus, Haemaphysalis longicornis, Page 40 of 71
41 Page 41 of 71 Haemaphysalis flava, Haemaphysalis campanulata) and lice within 48 hours postexposure. (S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects. This compound mimics the action of juvenile hormone and causes impaired development and death of the developing stages of fleas. The on-animal ovicidal activity of (S)-methoprene results from either direct penetration of the eggshell of newly laid eggs or from absorption through the cuticle of the adult fleas. (S)-methoprene is also effective in preventing flea larvae and pupae from developing, which prevents contamination of the environment of treated animals with the immature stages of fleas. 5.2 Pharmacokinetic particulars Studies of metabolism of fipronil have demonstrated that the major metabolite is the sulfone derivative of fipronil. (S)-methoprene is extensively degraded into carbon dioxide and acetate that are subsequently incorporated into endogenous materials. The pharmacokinetic profiles after topical application of fipronil and (S)-methoprene in combination were studied in cats in comparison to intravenous dosing of fipronil or (S)-methoprene alone. This established absorption and other pharmacokinetic parameters under conditions mimicking clinical practice. The topical application, with additional potential oral exposure from licking, resulted in overall systemic absorption of fipronil (18%) with a mean maximum concentration (Cmax) of approximately 100 ng/ml fipronil and 13 ng/ml of fipronil sulfone in plasma. Peak fipronil plasma concentrations are rapidly attained (mean tmax approximately 6 h) and decline with a mean terminal half-life of approximately 25 h. Fipronil is slightly metabolised to fipronil sulfone in cats. Plasma concentrations of (S)-methoprene were generally below the limit of quantitation (20 ng/ml) in cats after topical application. Both (S)-methoprene and fipronil, together with its major metabolite, are welldistributed in the haircoat of cats within one day after application. The concentrations of fipronil, fipronil sulfone and (S)-methoprene in the hair coat decrease with time and are detectable for at least 59 days after dosing. Parasites are killed through contact rather than by systemic exposure. No pharmacological interaction between fipronil and (S)-methoprene was noted. The pharmacokinetic profile of the product has not been investigated in ferrets. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Ethanol anhydrous Polysorbate 80 Povidone K17
42 Diethylene glycol monoethyl ether 6.2 Major incompatibilities None known. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years 6.4 Special precautions for storage Store in the original package in order to protect from light and moisture. This veterinary medicinal product does not require any special temperature storage conditions. 6.5 Nature and composition of immediate packaging 0.5 ml pipette, moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4- ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12 or 24 pipettes. Each pipette is individually sealed in a foil sachet. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Fipronil and (S)-methoprene may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty containers. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/4417 Page 42 of 71
43 9. DATE OF FIRST AUTHORISATION 16 May DATE OF REVISION OF THE TEXT January 2018 PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. Approved: 19 January 2018 Page 43 of 71
44 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PestiGon Combo 67 mg / 60.3 mg spot-on solution for small dogs (IE, BG, FR, HR, CY, CZ, EE, EL, HU, IT, LV, LT, MT, PT, RO, SK, ES, UK) Bolfo Combo 67 mg / 60.3 mg spot-on solution for small dogs (DE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pipette of 0.67 ml contains: Active substances: Fipronil mg (S)-methoprene mg Excipients: Butylhydroxyanisole (E320) mg Butylhydroxytoluene (E321) mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, yellow solution 4. CLINICAL PARTICULARS 4.1 Target species Dogs. 4.2 Indications for use, specifying the target species For the treatment of dogs weighing 2 to 10 kg bodyweight. To be used against infestations with fleas, alone or in association with ticks and/or biting lice. Treatment of flea infestations (Ctenocephalides spp.). Insecticidal efficacy against new infestations with adult fleas persist for 8 weeks. Prevention of the multiplication of fleas by inhibiting the development of eggs (ovicidal activity) and larvae and pupae (larvicidal activity) originating from eggs laid by adult fleas for eight weeks after application. Treatment of tick infestations (Ixodes ricinus, Dermacentor variabilis, Dermacentor reticulatus, Rhipicephalus sanguineus). The product has a persistent acaricidal efficacy for up to 4 weeks against ticks. Treatment of infestations with biting lice (Trichodectes canis). Page 44 of 71
45 Page 45 of 71 The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). 4.3 Contraindications In the absence of available data, the product should not be used on puppies less than 8 weeks old and/or weighing less than 2 kg. Do not use on sick (e.g. systemic diseases, fever) or convalescent animals. Do not use in rabbits, as adverse reactions with even mortality could occur. In the absence of studies, the use of the product is not recommended in non-target species. This product is specifically developed for dogs. Do not use in cats and ferrets, as this could lead to overdosing. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 4.4 Special warnings for each target species Bathing/immersion in water within 2 days after application of the product and more frequent bathing than once a week should be avoided, as no study has been performed to investigate how this affects the efficacy of the product. Emollient shampoos can be used prior to treatment, but reduce the duration of protection against fleas to approximately 5 weeks when used weekly after application of the product. Weekly bathing with a 2% chlorhexidine medicated shampoo did not affect efficacy against fleas during a 6 week long study. Dogs should not be allowed to swim in watercourses for 2 days after application (See section 6.6) There may be an attachment of a few ticks. For this reason a transmission of infectious diseases cannot be completely excluded if conditions are unfavorable. Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. 4.5 Special precautions for use Special precautions for use in animals Avoid contact with the animal s eyes. It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment. Special precautions to be taken by the person administering the veterinary medicinal product to animals This product can cause mucous membrane, skin and eye irritation. Therefore, contact of the product with mouth, skin and eyes should be avoided. In case of accidental eye contact, immediately and thoroughly rinse the eyes with clean water. If eye irritation persists seek medical advice and show the package leaflet or the label to the physician. If contact with the skin occurs, wash hands with soap and water. People with a known hypersensitivity to insecticides or alcohol should avoid contact with the veterinary medicinal product.
46 Wash hands after use. Ingestion of the product is harmful. Prevent children getting access to the pipettes and discard the used pipettes immediately after applying the product. In case of accidental ingestion of product, seek medical advice immediately. Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children. 4.6 Adverse reactions (frequency and seriousness) Among the very rare suspected adverse reactions, transient skin reactions on the application site (skin discoloration, local hair loss, itching, redness) and general itching or hair loss have been reported after use. Excessive salivation, reversible nervous signs (increased sensitivity to stimulation, depression, other nervous signs), vomiting or respiratory symptoms have also been observed after use. The frequency of adverse reactions is defined using the following convention: - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). If licking occurs, a brief period of excessive salivation may be observed due mainly to the nature of the carrier. Do not overdose. 4.7 Use during pregnancy, lactation or lay The product can be used during pregnancy and lactation. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route Dosage: One pipette of 0.67 ml per dog weighing over 2 and up to 10 kg, corresponding to a minimum recommended dose of 6.7 mg/kg for fipronil and 6 mg/kg for (S)-methoprene. In the absence of safety studies, the minimum treatment interval is 4 weeks. Route of administration: External use only, spot-on use. Only remove pipette from sachet immediately prior to use. Method of Administration: Page 46 of 71
47 Remove the pipette from the outer sachet using scissors or fold along diagonal line to expose nick; tear back at nick. Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Twist or snap back the tip. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot. Temporary changes to the coat (clumped/greasy hair) may be noted at the application site Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse effects were observed in target animal safety studies in 8 week-old puppies, growing dogs and dogs weighing about 2 kg treated once at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal period(s) Not applicable. Page 47 of 71
48 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Ectoparasiticides for topical use, fipronil combinations. ATCvet code: QP53AX Pharmacodynamic properties Fipronil is an insecticide and acaricide belonging to the phenylpyrazole family. It acts by interacting with ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and postsynaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarines. Fipronil kills fleas within 24 hours and ticks (Dermacentor reticulatus, Dermacentor variabilis, Rhipicephalus sanguineus, Ixodes scapularis, Ixodes ricinus, Haemaphysalis longicornis, Haemaphysalis flava, Haemaphysalis campanulata) and lice within 48 hours post-exposure. (S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects. This compound mimics the action of juvenile hormone and causes impaired development and death of the developing stages of fleas. The on-animal ovicidal activity of (S)-methoprene results from either direct penetration of the eggshell of newly laid eggs or from absorption through the cuticle of the adult fleas. (S)-methoprene is also effective in preventing flea larvae and pupae from developing, which prevents contamination of the environment of treated animals with the immature stages of fleas. 5.2 Pharmacokinetic particulars Studies of metabolism of fipronil have demonstrated that the major metabolite is the sulfone derivative of fipronil. (S)-methoprene is extensively degraded into carbon dioxide and acetate that are subsequently incorporated into endogenous materials. The pharmacokinetic profiles after topical application of fipronil and (S)-methoprene in combination were studied in dogs in comparison to intravenous dosing of fipronil or (S)-methoprene alone. This established absorption and other pharmacokinetic parameters. The topical application resulted in low systemic absorption of fipronil (11%) with a mean maximum concentration (Cmax) of approximately 35 ng/ml fipronil and 55 ng/ml of fipronil sulfone in plasma. Peak fipronil plasma concentrations are slowly attained (mean tmax approximately 101 h), and decline slowly (mean terminal half-life approximately 154 h, highest values are observed for males). Fipronil is extensively metabolised to fipronil sulfone after topical administration. Plasma concentrations of (S)-methoprene were below the limit of quantitation (20 ng/ml) in dogs after topical application. Both (S)-methoprene and fipronil, together with its major metabolite, are welldistributed in the haircoat of a dog within one day after application. The concentrations of fipronil, fipronil sulfone and S-methoprene in the hair coat decrease with time and are detectable for at least 60 days after dosing. Parasites are killed through contact rather than systemic exposure. Page 48 of 71
49 No pharmacological interaction between fipronil and (S)-methoprene was noted. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Ethanol anhydrous Polysorbate 80 Povidone K17 Diethylene glycol monoethyl ether 6.2 Major incompatibilities None known. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years 6.4. Special precautions for storage Store in the original package in order to protect from light and moisture. This veterinary medicinal product does not require any special temperature storage conditions. 6.5 Nature and composition of immediate packaging 0.67 ml pipette, moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4- ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12 or 24 pipettes. Each pipette is individually sealed in a foil sachet. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Fipronil and (S)-methoprene may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty containers. Page 49 of 71
50 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 16 May DATE OF REVISION OF THE TEXT January 2018 PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. Approved: 19 January 2018 Page 50 of 71
51 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PestiGon Combo 134 mg / mg spot-on solution for medium dogs (IE, BG, FR, HR, CY, CZ, EE, EL, HU, IT, LV, LT, MT, PT, RO, SK, ES, UK) Bolfo Combo 134 mg / mg spot-on solution for medium dogs (DE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pipette of 1.34 ml contains: Active substances: Fipronil mg (S)-methoprene mg Excipients: Butylhydroxyanisole (E320) mg Butylhydroxytoluene (E321) mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, yellow solution. 4. CLINICAL PARTICULARS 4.1 Target species Dogs. 4.2 Indications for use, specifying the target species For the treatment of dogs weighing 10 to 20 kg bodyweight: To be used against infestations with fleas, alone or in association with ticks and/or biting lice. Treatment of flea infestations (Ctenocephalides spp.). Insecticidal efficacy against new infestations with adult fleas persists for 8 weeks. Prevention of the multiplication of fleas by inhibiting of the development of eggs (ovicidal activity) and larvae and pupae (larvicidal activity) originating from eggs laid by adult fleas for eight weeks after application. Treatment of tick infestations (Ixodes ricinus, Dermacentor variabilis, Dermacentor reticulatus, Rhipicephalus sanguineus). The product has a persistent acaricidal efficacy for up to 4 weeks against ticks. Treatment of infestations with biting lice (Trichodectes canis). Page 51 of 71
52 Page 52 of 71 The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). 4.3 Contraindications In the absence of available data, the product should not be used on puppies less than 8 weeks old. Do not use on sick (e.g. systemic diseases, fever) or convalescent animals. Do not use in rabbits, as adverse reactions with even mortality could occur. In absence of studies, the use of the product is not recommended in non-target species. This product is specifically developed for dogs. Do not use in cats and ferrets, as this could lead to overdosing. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 4.4 Special warnings for each target species Bathing/immersion in water within 2 days after application of the product and more frequent bathing than once a week should be avoided, as no study has been performed to investigate how this affects the efficacy of the product. Emollient shampoos can be used prior to treatment, but reduce the duration of protection against fleas to approximately 5 weeks when used weekly after application of the product. Weekly bathing with a 2% chlorhexidine medicated shampoo did not affect efficacy against fleas during a 6 week long study. Dogs should not be allowed to swim in watercourses for 2 days after application (see section 6.6). There may be an attachment of a few ticks. For this reason a transmission of infectious diseases cannot be completely excluded if conditions are unfavourable. Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. 4.5 Special precautions for use Special precautions for use in animals Avoid contact with the animal s eyes. It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment. Special precautions to be taken by the person administering the veterinary medicinal product to animals This product can cause mucous membrane, skin and eye irritation. Therefore, contact of the product with mouth, skin and eyes should be avoided. In case of accidental eye contact, immediately and thoroughly rinse the eyes with clean water. If eye irritation persists seek medical advice and show the package leaflet or the label to the physician. If contact with the skin occurs, wash hands with soap and water.
53 People with a known hypersensitivity to insecticides or alcohol should avoid contact with the veterinary medicinal product. Wash hands after use. Ingestion of the product is harmful. Prevent children getting access to the pipettes and discard the used pipettes immediately after applying the product. In case of accidental ingestion of product, seek medical advice immediately. Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children. 4.6 Adverse reactions (frequency and seriousness) Among the very rare suspected adverse reactions, transient skin reactions on the application site (skin discoloration, local hair loss, itching,redness) and general itching or hair loss have been reported after use. Excessive salivation, reversible nervous signs (increased sensitivity to stimulation, depression, other nervous signs), vomiting or respiratory symptoms have also been observed after use. The frequency of adverse reactions is defined using the following convention: - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). If licking occurs, a brief period of excessive salivation may be observed due mainly to the nature of the carrier. Do not overdose. 4.7 Use during pregnancy, lactation or lay The product can be used during pregnancy and lactation. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route Dosage: One pipette of 1.34 ml per dog weighing over 10 kg and up to 20 kg, corresponding to a minimum recommended dose of 6.7 mg/kg for fipronil and 6 mg/kg for (S)-methoprene. In the absence of safety studies the minimum treatment interval is 4 weeks. Route of administration: External use only, spot-on use. Only remove pipette from sachet immediately prior to use. Page 53 of 71
54 Method of Administration: Remove the pipette from the outer sachet using scissors or fold along diagonal line to expose nick; tear back at nick. Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Twist or snap back the tip. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot. Temporary changes to the coat (clumped/greasy hair) may be noted at the application site Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse effects were observed in target animal safety studies in 8 week-old puppies, growing dogs and dogs weighing about 2 kg treated once at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal period(s) Not applicable. Page 54 of 71
55 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Ectoparasiticides for topical use, fipronil combinations. ATCvet code: QP53AX Pharmacodynamic properties Fipronil is an insecticide and acaricide belonging to the phenylpyrazole family. It acts by interacting with ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and postsynaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarines. Fipronil kills fleas within 24 hours and ticks (Dermacentor reticulatus, Dermacentor variabilis, Rhipicephalus sanguineus, Ixodes scapularis, Ixodes ricinus, Haemaphysalis longicornis, Haemaphysalis flava, Haemaphysalis campanulata) and lice within 48 hours post-exposure. (S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects. This compound mimics the action of juvenile hormone and causes impaired development and death of the developing stages of fleas. The on-animal ovicidal activity of (S)-methoprene results from either direct penetration of the eggshell of newly laid eggs or from absorption through the cuticle of the adult fleas. (S)-methoprene is also effective in preventing flea larvae and pupae from developing, which prevents contamination of the environment of treated animals with the immature stages of fleas. 5.2 Pharmacokinetic particulars Studies of metabolism of fipronil have demonstrated that the major metabolite is the sulfone derivative of fipronil. (S)-methoprene is extensively degraded into carbon dioxide and acetate that are subsequently incorporated into endogenous materials. The pharmacokinetic profiles after topical application of fipronil and (S)-methoprene in combination were studied in dogs in comparison to intravenous dosing of fipronil or (S)-methoprene alone. This established absorption and other pharmacokinetic parameters. The topical application resulted in low systemic absorption of fipronil (11%) with a mean maximum concentration (Cmax) of approximately 35 ng/ml fipronil and 55 ng/ml of fipronil sulfone in plasma. Peak fipronil plasma concentrations are slowly attained (mean tmax approximately 101 h), and decline slowly (mean terminal half-life approximately 154 h, highest values are observed for males). Fipronil is extensively metabolised to fipronil sulfone after topical administration. Plasma concentrations of (S)-methoprene were below the limit of quantitation (20 ng/ml) in dogs after topical application. Both (S)-methoprene and fipronil, together with its major metabolite, are welldistributed in the haircoat of a dog within one day after application. The concentrations of fipronil, fipronil sulfone and S-methoprene in the hair coat decrease Page 55 of 71
56 with time and are detectable for at least 60 days after dosing. Parasites are killed through contact rather than systemic exposure. No pharmacological interaction between fipronil and (S)-methoprene was noted. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Ethanol anhydrous Polysorbate 80 Povidone K17 Diethylene glycol monoethyl ether 6.2 Major incompatibilities None known. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years 6.4 Special precautions for storage Store in the original package in order to protect from light and moisture. This veterinary medicinal product does not require any special temperature storage conditions. 6.5 Nature and composition of immediate packaging 1.34 ml pipette, moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4- ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes. Each pipette is individually sealed in a foil sachet. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Page 56 of 71
57 Fipronil and (S)-methoprene may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty containers. 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 16 May DATE OF REVISION OF THE TEXT January 2018 PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. Approved: 19 January 2018 Page 57 of 71
58 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PestiGon Combo 268 mg / mg spot-on solution for large dogs (IE, BG, FR, HR, CY, CZ, EE, DE, EL, HU, IT, LV, LT, MT, PT, RO, SK, ES, UK) Bolfo Combo 268 mg / mg spot-on solution for large dogs (DE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pipette of 2.68 ml contains: Active substances: Fipronil mg (S)-methoprene mg Excipients: Butylhydroxyanisole (E320) mg Butylhydroxytoluene (E321) mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, yellow solution 4. CLINICAL PARTICULARS 4.1 Target species Dogs 4.2 Indications for use, specifying the target species For the treatment of dogs weighing 20 to 40 kg bodyweight. To be used against infestations with fleas, alone or in association with ticks and/or biting lice. Treatment of flea infestations (Ctenocephalides spp.). Insecticidal efficacy against new infestations with adult fleas persists for 8 weeks. Prevention of the multiplication of fleas by inhibiting the development of eggs (ovicidal activity) and larvae and pupae (larvicidal activity) originating from eggs laid by adult fleas for eight weeks after application. Treatment of tick infestations (Ixodes ricinus, Dermacentor variabilis, Dermacentor reticulatus, Rhipicephalus sanguineus). The product has persistent acaricidal efficacy for up to 4 weeks against ticks. Treatment of infestations with biting lice (Trichodectes canis). The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). Page 58 of 71
59 4.3 Contraindications In the absence of available data, the product should not be used on puppies less than 8 weeks old. Do not use in rabbits, as adverse reactions with even mortality could occur. In absence of studies, the use of the product is not recommended in non-target species. Do not use on sick (e.g. systemic diseases, fever) or convalescent animals. This product is specifically developed for dogs. Do not use in cats and ferrets, as this could lead to overdosing. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 4.4 Special warnings for each target species Bathing/immersion in water within 2 days after application of the product and more frequent bathing than once a week should be avoided, as no study has been performed to investigate how this affects the efficacy of the product. Emollient shampoos can be used prior to treatment, but reduce the duration of protection against fleas to approximately 5 weeks when used weekly after application of the product Weekly bathing with a 2% chlorhexidine medicated shampoo did not affect efficacy against fleas during a 6 week long study. Dogs should not be allowed to swim in watercourses for 2 days after application (see section 6.6). There may be an attachment of a few ticks. For this reason a transmission of infectious diseases cannot be completely excluded if conditions are unfavourable. Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. 4.5 Special precautions for use Special precautions for use in animals Avoid contact with the animal s eyes. It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment. Special precautions to be taken by the person administering the veterinary medicinal product to animals This product can cause mucous membrane, skin and eye irritation. Therefore, contact of the product with mouth, skin and eyes should be avoided. In case of accidental eye contact, immediately and thoroughly rinse the eyes with clean water. If eye irritation persists seek medical advice and show the package leaflet or the label to the physician. If contact with the skin occurs, wash hands with soap and water. People with a known hypersensitivity to insecticides or alcohol should avoid contact with the veterinary medicinal product. Page 59 of 71
60 Wash hands after use. Ingestion of the product is harmful. Prevent children getting access to the pipettes and discard the used pipettes immediately after applying the product. In case of accidental ingestion of product, seek medical advice immediately. Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children. 4.6 Adverse reactions (frequency and seriousness) Among the very rare suspected adverse reactions, transient skin reactions on the application site (skin discoloration, local hair loss, itching, redness) and general itching or hair loss have been reported after use. Excessive salivation, reversible nervous signs (increased sensitivity to stimulation, depression, other nervous signs), vomiting or respiratory symptoms have also been observed after use. The frequency of adverse reactions is defined using the following convention: - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). If licking occurs, a brief period of excessive salivation may be observed due mainly to the nature of the carrier. Do not overdose. 4.7 Use during pregnancy, lactation or lay The product can be used during pregnancy and lactation. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route Dosage: one pipette of 2.68 ml per dog weighing over 20 kg and up to 40 kg, corresponding to a minimum recommended dose of 6.7 mg/kg for fipronil and 6 mg/kg for (S)-methoprene. In the absence of safety studies, the minimum treatment interval is 4 weeks. Route of administration: External use only, spot-on use. Only remove pipette from sachet immediately prior to use. Method of Administration: Page 60 of 71
61 Remove the pipette from the outer sachet using scissors or fold along diagonal line to expose nick; tear back at nick. Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Twist or snap back the tip. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot. Temporary changes to the coat (clumped/greasy hair) may be noted at the application site Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse effects were observed in target animal safety studies in 8 week-old puppies, growing dogs and dogs weighing about 2 kg treated once at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal period(s) Not applicable. Page 61 of 71
62 5. PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Ectoparasiticides for topical use, fipronil combinations. ATCvet code: QP53AX Pharmacodynamic properties Fipronil is an insecticide and acaricide belonging to the phenylpyrazole family. It acts by interacting with ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and postsynaptic transfer of chloride ions across cell membranes. This results in uncontrolled activity of the central nervous system and death of insects or acarines. Fipronil kills fleas within 24 hours and ticks (Dermacentor reticulatus, Dermacentor variabilis, Rhipicephalus sanguineus, Ixodes scapularis, Ixodes ricinus, Haemaphysalis longicornis, Haemaphysalis flava, Haemaphysalis campanulata) and lice within 48 hours post-exposure. (S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects. This compound mimics the action of juvenile hormone and causes impaired development and death of the developing stages of fleas. The on-animal ovicidal activity of (S)-methoprene results from either direct penetration of the eggshell of newly laid eggs or from absorption through the cuticle of the adult fleas. (S)-methoprene is also effective in preventing flea larvae and pupae from developing, which prevents contamination of the environment of treated animals with the immature stages of fleas. 5.2 Pharmacokinetic particulars Studies of metabolism of fipronil have demonstrated that the major metabolite is the sulfone derivative of fipronil. (S)-methoprene is extensively degraded into carbon dioxide and acetate that are subsequently incorporated into endogenous materials. The pharmacokinetic profiles after topical application of fipronil and (S)-methoprene in combination were studied in dogs in comparison to intravenous dosing of fipronil or (S)-methoprene alone. This established absorption and other pharmacokinetic parameters. The topical application resulted in low systemic absorption of fipronil (11%) with a mean maximum concentration (Cmax) of approximately 35 ng/ml fipronil and 55 ng/ml of fipronil sulfone in plasma. Peak fipronil plasma concentrations are slowly attained (mean tmax approximately 101 h), and decline slowly (mean terminal half-life approximately 154 h, highest values are observed for males). Fipronil is extensively metabolised to fipronil sulfone after topical administration. Plasma concentrations of (S)-methoprene were below the limit of quantitation (20 ng/ml) in dogs after topical application. Both (S)-methoprene and fipronil, together with its major metabolite, are welldistributed in the haircoat of a dog within one day after application. The concentrations of fipronil, fipronil sulfone and S-methoprene in the hair coat decrease Page 62 of 71
63 Page 63 of 71 with time and are detectable for at least 60 days after dosing. Parasites are killed through contact rather than systemic exposure. No pharmacological interaction between fipronil and (S)-methoprene was noted. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Butylhydroxyanisole (E320) Butylhydroxytoluene (E321) Ethanol anhydrous Polysorbate 80 Povidone K17 Diethylene glycol monoethyl ether 6.2 Major incompatibilities None known. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years 6.4 Special precautions for storage Store in the original package in order to protect from light and moisture. This veterinary medicinal product does not require any special temperature storage conditions. 6.5 Nature and composition of immediate packaging 2.68 ml pipette, moulded from a film composed of 3 layers: a polypropylene/coc/polypropylene, solvent free lacquer laminate and a copolymer of polyethylene/evoh/polyethylene. The pipettes are sealed within a child resistant 4- ply foil sachet composed of LDPE/nylon/aluminium foil/polyester film and presented in an outer box. Boxes of 1, 2, 3, 4, 6, 8, 12, 24, 30, 60, 90, 120 or 150 pipettes. Each pipette is individually sealed in a foil sachet. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Fipronil and (S)-methoprene may adversely affect aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty containers.
64 7. MARKETING AUTHORISATION HOLDER Norbrook Laboratories Limited Station Works Camlough Road Newry Co. Down BT35 6JP Northern Ireland 8. MARKETING AUTHORISATION NUMBER Vm 02000/ DATE OF FIRST AUTHORISATION 16 May DATE OF REVISION OF THE TEXT January 2018 PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. Approved: 19 January 2018 Page 64 of 71
65 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PestiGon Combo 402 mg / mg spot-on solution for very large dogs (IE, BG, FR, HR, CY, CZ, EE, DE, EL, HU, IT, LV, LT, MT, PT, RO, SK, ES, UK) Bolfo Combo 402 mg / mg spot-on solution for very large dogs (DE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pipette of 4.02 ml contains: Active substances: Fipronil mg (S)-methoprene mg Excipients: Butylhydroxyanisole (E320) mg Butylhydroxytoluene (E321) mg For the full list of excipients, see section PHARMACEUTICAL FORM Spot-on solution. A clear, yellow solution 4. CLINICAL PARTICULARS 4.1 Target species Dogs 4.2 Indications for use, specifying the target species For the treatment of dogs weighing over 40 kg bodyweight: To be used against infestations with fleas, alone or in association with ticks and/or biting lice. Treatment of flea infestations (Ctenocephalides spp.). Insecticidal efficacy against new infestations with adult fleas persists for 8 weeks. Prevention of the multiplication of fleas by inhibiting the development of eggs (ovicidal activity) and larvae and pupae (larvicidal activity) originating from eggs laid by adult fleas for eight weeks after application. Treatment of tick infestations (Ixodes ricinus, Dermacentor variabilis, Dermacentor reticulatus, Rhipicephalus sanguineus). The product has a persistent acaricidal efficacy for up to 4 weeks against ticks. Treatment of infestations with biting lice (Trichodectes canis). The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). Page 65 of 71
66 4.3 Contraindications In the absence of available data, the product should not be used on puppies less than 8 weeks old Do not use in rabbits, as adverse reactions with even mortality could occur. In absence of studies, the use of the product is not recommended in non-target species. Do not use on sick (e.g. systemic diseases, fever) or convalescent animals. This product is specifically developed for dogs. Do not use in cats and ferrets, as this could lead to overdosing. Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 4.4 Special warnings for each target species Bathing/immersion in water within 2 days after application of the product and more frequent bathing than once a week should be avoided, as no study has been performed to investigate how this affects the efficacy of the product. Emollient shampoos can be used prior to treatment, but reduce the duration of protection against fleas to approximately 5 weeks when used weekly after application of the product. Weekly bathing with a 2% chlorhexidine medicated shampoo did not affect efficacy against fleas during a 6 week long study. Dogs should not be allowed to swim in watercourses for 2 days after application (See section 6.6) There may be an attachment of a few ticks. For this reason a transmission of infectious diseases cannot be completely excluded if conditions are unfavorable. Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly. 4.5 Special precautions for use Special precautions for use in animals Avoid contact with the animal s eyes. It is important to make sure that the product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment. Special precautions to be taken by the person administering the veterinary medicinal product to animals This product can cause mucous membrane, skin and eye irritation. Therefore, contact of the product with mouth, skin and eyes should be avoided. In case of accidental eye contact, immediately and thoroughly rinse the eyes with clean water. If eye irritation persists seek medical advice and show the package leaflet or the label to the physician. If contact with the skin occurs, wash hands with soap and water. People with a known hypersensitivity to insecticides or alcohol should avoid contact with the veterinary medicinal product. Page 66 of 71
67 Wash hands after use. Ingestion of the product is harmful. Prevent children getting access to the pipettes and discard the used pipettes immediately after applying the product. In case of accidental ingestion of product, seek medical advice immediately. Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children. 4.6 Adverse reactions (frequency and seriousness) Among the very rare suspected adverse reactions, transient skin reactions on the application site (skin discoloration, local hair loss, itching, redness) and general itching or hair loss have been reported after use. Excessive salivation, reversible nervous signs (increased sensitivity to stimulation, depression, other nervous signs), vomiting or respiratory symptoms have also been observed after use. The frequency of adverse reactions is defined using the following convention: - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). If licking occurs, a brief period of excessive salivation may be observed due mainly to the nature of the carrier. Do not overdose. 4.7 Use during pregnancy, lactation or lay The product can be used during pregnancy and lactation. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route Dosage: one pipette of 4.02 ml per dog weighing over 40 kg, corresponding to a minimum recommended dose of 6.7 mg/kg for fipronil and 6 mg/kg for (S)- methoprene. Route of administration: External use only, spot-on use. Only remove pipette from sachet immediately prior to use. Method of Administration: Remove the pipette from the outer sachet using scissors or fold along diagonal line to expose nick; tear back at nick. Page 67 of 71
68 Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Twist or snap back the tip. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot. Temporary changes to the coat (clumped/greasy hair) may be noted at the application site Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse effects were observed in target animal safety studies in 8 week-old puppies, growing dogs and dogs weighing about 2 kg treated once at five times the recommended dose. The risk of experiencing adverse effects (see section 4.6) may however increase when overdosing, so animals should always be treated with the correct pipette size according to bodyweight Withdrawal period(s) Not applicable. Page 68 of 71
SUMMARY OF PRODUCT CHARACTERISTICS FOR CATS
SUMMARY OF PRODUCT CHARACTERISTICS FOR CATS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT EFFIPRO 50 mg spot-on solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One 0.5 ml pipette contains :
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fiprex CAT 52.5 mg spot-on solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pipette (0.7 ml) contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fiprex S 75 mg spot-on solution for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pipette (1 ml) contains: Active
More informationFrontline Combo Pack Consult Spot on Dog L SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FRONTLINE COMBO PACK CONSULT SPOT-ON DOG L [FR] FRONTLINE Combo Spot On Clinic Pack Hond/Chien/Hund L [BE,LU] COMBOLINE
More informationFrontline Combo Pack Consult Spot on Cat SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FRONTLINE COMBO PACK CONSULT SPOT-ON CAT [FR] FRONTLINE Combo Spot On Clinic Pack Kat/Chat/Katze [BE, LU] COMBOLINE Spot
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMFLEE combo 50 mg/60 mg spot-on solution for cats and ferrets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.5 ml pipette
More informationSUMMARY OF PRODUCT CHARACTERSITICS
SUMMARY OF PRODUCT CHARACTERSITICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eliminall 2.5 mg/ml cutaneous spray, solution for cats and dogs Exproline vet 2.5 mg/ml cutaneous spray, solution for cats
More informationFluralaner (mg) for small cats kg for medium-sized cats > kg for large cats > kg 1.
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bravecto 112.5 mg spot-on solution for small cats (1.2 2.8 kg) Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 6.25 kg) Bravecto 500 mg spot-on
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Pestigon 50 mg Spot-On Solution for Cats Pestigon vet 50 mg
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Activyl Tick Plus 75 mg + 240 mg spot-on solution for very small dogs Activyl Tick Plus 150 mg + 480 mg spot-on
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NexGard 11 mg chewable tablets for dogs 2-4 kg NexGard 28 mg chewable tablets for dogs > 4-10 kg NexGard 68 mg chewable
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vectra Felis 423 mg/42.3 mg spot-on solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances:
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: Imidacloprid 40 mg/pipette (0.4 ml of a 10 % solution)
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Advantage 40 Spot-on Solution for 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Imidacloprid 40 mg/pipette
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Credelio 56 mg chewable tablets for dogs (1.3 2.5 kg) Credelio 112 mg chewable tablets for dogs (>2.5 5.5 kg) Credelio
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Advantage 40 Spot-on solution for Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Imidacloprid 40 mg/pipette
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Advantage 40 mg feline and bunny Spot-on solution [UK] Advantage 40 mg Spot-on solution for Small Cats and Small Pet Rabbits
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NexGard 11 mg chewable tablets for dogs 2 4 kg NexGard 28 mg chewable tablets for dogs >4 10 kg NexGard 68 mg chewable
More informationPlease refer to Table 1 Dosage and Treatment Schedule TABLE 1 Species Product Number of Tubes Cats. Rabbits or Advantage 40 for Cats
Advantage Introduction Company name: Bayer plc Address: Animal Health Division Bayer House, Strawberry Hill, Newbury Berkshire RG14 1JA Telephone: 01635 563000 Fax: 01635 563622 Email: animal.health@bayerhealthcare.com
More informationMUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) Federal Office of Consumer Protection and Food Safety Mauerstraße 39-42 10117 Berlin (Germany) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE, ES, FR, PT] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT TAF SPRAY 28.5 mg/g Cutaneous Spray, Solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g contains: Active substance: Thiamphenicol
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vectra 3D spot-on solution for dogs 1.5 4 kg Vectra 3D spot-on solution for dogs 4 10 kg Vectra 3D spot-on solution
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Issued March 2017 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Recicort 1.77 mg/ml + 17.7 mg/ml ear drops, solution for dogs and cats Recicort vet 1.77 mg/ml + 17.7 mg/ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Revised: September 2015 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Frento Forte Flohschutztropfen 40mg Lösung zum Auftropfen für kleine Katzen [AT] ADVANTAGE 40 voor
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bravecto 112.5 mg chewable tablets for very small dogs (2-4.5 kg) Bravecto 250 mg chewable tablets for small dogs
More informationLABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acecare 2mg/ml Solution for Injection for Dogs and Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2-10 kg CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Equest Oral Gel, 18,92 mg/g, Oral Gel for Horses and Ponies
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equest Oral Gel, 18,92 mg/g, Oral Gel for Horses and Ponies (Sweden: Cydectin Vet) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationMOXIDECTIN SPOT-ON SOLUTION FOR KITTENS AND SMALL CATS. 280 mg/ml FLURALANER 14 mg/ml MOXIDECTIN Also contains: 339 mg/ml DIMETHYLACETAMIDE (solvent)
Product Name: BRAVECTO PLUS FLEA, TICK AND WORM 112.5 MG FLURALANER AND 5.6 MG MOXIDECTIN SPOT-ON SOLUTION FOR KITTENS AND SMALL CATS APVMA Approval No: 85418/113229 Label Name: BRAVECTO PLUS FLEA, TICK
More informationFor the treatment and prevention of infections caused by:
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYDECTIN 0.1 % W/V ORAL SOLUTION for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance Moxidectin
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Zeronil 402 mg Spot-on Solution for extra large dogs CMD(v)/TEM/003-00
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bravecto 112.5 mg chewable tablets for very small dogs (2 4.5 kg) Bravecto 250 mg chewable tablets for small dogs
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Zeronil 50 mg Spot-on Solution for cats CMD(v)/TEM/003-00
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Simparica 5 mg chewable tablets for dogs 1.3 2.5 kg Simparica 10 mg chewable tablets for dogs >2.5 5 kg Simparica
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prinovox 80 mg + 8 mg spot-on solution for large cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.8 ml pipette contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMPROLINE 400 mg/ml solution for use in drinking water for chickens and turkeys 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Amphen 200 mg/g Granules for use in drinking water for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g contains: Active
More informationFLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER
FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cydectin 1% w/v Injectable Solution for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Moxidectin Excipients
More informationFor the treatment of mixed parasitic infections in cats caused by roundworms and tapeworms of the following species:
Printed from (http://www.noahcompendium.co.uk). (c) Copyright 2018. All Rights Reserved. Date: Wednesday, October 24, 2018 11:47 Bayer plc Telephone:0118 206 3000 Website:www.bayer.co.uk Email:animal.health@bayer.com
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Distocur 34 mg/ml Oral suspension for cattle. Distocur.vet 34 mg/ml Oral suspension for cattle. (DK, NO, SE) 2.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationUbroseal Dry Cow 2.6 g intramammary suspension for cattle
Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ubroseal Dry Cow 2.6 g intramammary suspension for cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 4g intramammary
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carofertin 10 mg/ml Emulsion for injection for cattle and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection
SUMMARY OF PRODUCT CHARACTERISTICS Revised: June 2018 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10999/033/001A Case No: 7006569 The in exercise of the powers conferred on it by Animal Remedies
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Malaseb shampoo for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substances: Chlorhexidine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationEar drops suspension. A smooth, uniform, white to off-white viscous suspension.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:
More informationFor the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:
SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Intra Hoof-Fit Gel 40 mg/g + 40 mg/g gel for dairy cattle Intra Pasta 40 mg/g + 40 mg/g gel for dairy cattle Pecopro vet
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Maprelin 75 µg/ml solution for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of Veterinary Medicinal Product Endofluke 100 mg/ml Oral Suspension 2. Qualitative and Quantitative Composition Active Substance per ml Triclabendazole 100mg
More informationHealth Products Regulatory Authority
Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Spotinor 10 mg/ml Spot-on Solution for cattle and sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active
More informationPART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN
PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Octacillin 800 mg/g powder for use in drinking water for chickens NL: Octacillin 800 mg/g poeder voor gebruik
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pro Penstrep Suspension for Injection for Cattle, Sheep and Pigs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Seresto 1.25 g + 0.56 g, collar for dogs 8 kg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: One collar of 38
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS
1.B. SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Lamox 800 mg/g powder for use in drinking water for chickens and pigs 2. QUALITATIVE
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 5% w/v Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Closantel (as Clostanel sodium)
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Xylacare 2% w/v Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Qualitative composition
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Oxycare 20 %w/v LA Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Oxytetracycline (Equivalent
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT IVOMEC Injection for Pigs 10 mg/ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Ivermectin
More information[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Curofen 50 mg/g Premix for Medicated Feeding Stuff for Pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationVetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Austria Belgium Cyprus Malta Czech Republic Netherlands Greece Portugal Slovakia Hungary Slovenia Germany Finland France Luxembourg
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS page 1 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur PetPaste 187.5 mg/g oral paste for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g oral
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HALOCUR 0.5 mg/ml oral solution for calves 2. Qualitative and quantitative composition Active substance Halofuginone
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Comfortis 270 mg chewable tablets for dogs Comfortis 425 mg chewable tablets for dogs Comfortis 665 mg chewable
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican Herpes 205 powder and solvent for emulsion for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationSUMMARY OF PRODUCTS CHARACTERISTICS
SUMMARY OF PRODUCTS CHARACTERISTICS Revised: 15 January 2009 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tramazole 2.5% w/v SC Oral Suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dipen 100ml Suspension for Injection for cattle, sheep and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ZANTEL 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Per tablet Praziquantel 50.0 mg Fenbendazole 500.0 mg
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCPCh lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, CZ, EE, ES, FR, IE, IS, IT, LT, LU, LV, NO, PL, PT, RO, SE, SI, SK, UK: Genestran 75 micrograms/ml solution for injection
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DOXYPRIM 40% soluble powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Doxycycline hyclate 400.0 mg Excipients:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More information[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pneumospectin 50 mg/ml +100 mg/ml solution for injection for cattle (calves), sheep, goat, pig,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Streptacare Suspension for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Each ml contains: Procaine
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK) Euthasol 400
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Advantage
More information[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Apivar 500 mg Amitraz Bee-hive strips for honey bees. UK: Apivar 500 mg Bee-hive strips for
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA: 10999/056/001 Case No: 7004318 The Irish Medicines Board in exercise of the powers
More informationFiprotec 50 mg Spot On Solution for Cats
College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Revised: January 2012 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Blackleg Vaccine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s): per ml Five strains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pentofel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1ml: Active components Inactivated Feline Panleukopenia
More information